Genetic testing for Bardet-Biedl syndrome

Abeshi A., Fanelli F., Beccari T., DÜNDAR M., D'Esposito F., Bertelli M.

EUROBIOTECH JOURNAL, cilt.1, ss.14-16, 2017 (ESCI) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 1
  • Basım Tarihi: 2017
  • Doi Numarası: 10.24190/issn2564-615x/2017/s1.04
  • Dergi Adı: EUROBIOTECH JOURNAL
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI)
  • Sayfa Sayıları: ss.14-16
  • Erciyes Üniversitesi Adresli: Evet

Özet

We studied the scientific literature and disease guidelines in order to summarize the clinical utility of genetic testing for Bardet-Biedl syndrome (BBS). The disease has autosomal recessive inheritance, a prevalence varying from one in 13 500 to one in 160 000, and is caused by mutations in the ARL6, BBIP1, BBS1, BBS2, BBS4, BBS5, BBS7, BBS9, BBS10, BBS12, CEP290, IFT172, IFT27, LZTFL1, MKKS, MKS1, NPHP1, SDCCAG8, TRIM32, TTC8 and WDPCP genes. The clinical diagnosis of BBS is based on four primary features or three primary features plus two secondary features. The genetic test is useful for confirming diagnosis, and for differential diagnosis, couple risk assessment and access to clinical trials.